Brock Recovery Ventures

Brock Recovery Ventures invests at the intersection of clinical science, technology, and lived experience. We look for companies attacking addiction and behavioral health at a systems level, not just managing symptoms, but rewiring the infrastructure of care, prevention, and long-term recovery.

Our thesis is specific: back founders who combine deep domain expertise with scalable business models that we can add significant value to given our extensive network and experience. We back companies where clinical outcomes and financial sustainability reinforce each other. We back the entire continuum of care, from genomic risk assessment before addiction develops to the sober living house where someone rebuilds their life after treatment.

We have preference for companies at the Seed/Series A stages, can lead rounds and take Director seats.

Where We Invest

Treatment & Clinical Services

Evidence-based treatment platforms, medication-assisted therapies, and clinical operations raising the standard of care
Biotech & Therapeutics

Pharmaceutical development targeting substance use disorders with novel mechanisms of action
Prevention & Genomics

Upstream interventions, risk assessment tools, and personalized prevention strategies
Technology & Digital Health

Telehealth, clinical decision support, and data-driven care platforms
Recovery Housing & Real Estate

Purpose-built residential infrastructure for recovery communities

San Francisco, CA

Baseline Therapeutics

Breakthrough therapeutics for addiction.

Morris Birnbaum, MD, PhD, CEO, Chief Scientific Officer & Co-founder | Nicholas Reville, Head of Strategy & Co-founder | Lindsay Holden, COO & Co-founder